ID   PYR1_HUMAN              Reviewed;        2225 AA.
AC   P27708; D6W552; Q6P0Q0; Q96CK3;
DT   01-AUG-1992, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 3.
DT   10-MAY-2017, entry version 200.
DE   RecName: Full=CAD protein;
DE   Includes:
DE     RecName: Full=Glutamine-dependent carbamoyl-phosphate synthase;
DE              EC=6.3.5.5 {ECO:0000269|PubMed:24332717};
DE   Includes:
DE     RecName: Full=Aspartate carbamoyltransferase;
DE              EC=2.1.3.2 {ECO:0000269|PubMed:24332717};
DE   Includes:
DE     RecName: Full=Dihydroorotase;
DE              EC=3.5.2.3 {ECO:0000269|PubMed:24332717};
GN   Name=CAD {ECO:0000312|HGNC:HGNC:1424};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal lung fibroblast;
RX   PubMed=8619816; DOI=10.1006/bbrc.1996.0213;
RA   Iwahana H., Fujimura M., Ii S., Kondo M., Moritani M., Takahashi Y.,
RA   Yamaoka T., Yoshimoto K., Itakura M.;
RT   "Molecular cloning of a human cDNA encoding a trifunctional enzyme of
RT   carbamoyl-phosphate synthetase-aspartate transcarbamoylase-
RT   dihydroorotase in de Novo pyrimidine synthesis.";
RL   Biochem. Biophys. Res. Commun. 219:249-255(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-13; 157-165; 169-177; 359-371; 501-516; 548-555;
RP   599-606; 697-719; 761-778; 843-854; 932-944; 1034-1048; 1067-1075;
RP   1110-1127; 1229-1240; 1263-1270; 1313-1323; 1326-1333; 1658-1667;
RP   1723-1731; 1840-1848; 1976-1986; 2025-2036; 2103-2110; 2179-2187 AND
RP   2215-2225, CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Colon adenocarcinoma, and Hepatoma;
RA   Bienvenut W.V., Dhillon A.S., Matallanas D., Murray L., Brunton V.G.,
RA   Cooper W.N., Boldt K., von Kriegsheim A.F., Kolch W., Frame M.C.;
RL   Submitted (FEB-2008) to UniProtKB.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1752-2225.
RX   PubMed=1979741; DOI=10.1089/dna.1990.9.667;
RA   Davidson J.N., Rao G.N., Niswander L., Andreano C., Tamer C.,
RA   Chen K.C.;
RT   "Organization and nucleotide sequence of the 3' end of the human CAD
RT   gene.";
RL   DNA Cell Biol. 9:667-676(1990).
RN   [6]
RP   MUTAGENESIS OF HIS-1471; HIS-1473; ASP-1512; HIS-1590; HIS-1642 AND
RP   HIS-1690, COFACTOR, AND ZINC-BINDING SITES.
RX   PubMed=7766613; DOI=10.1021/bi00021a015;
RA   Zimmermann B.H., Kemling N.M., Evans D.R.;
RT   "Function of conserved histidine residues in mammalian
RT   dihydroorotase.";
RL   Biochemistry 34:7038-7046(1995).
RN   [7]
RP   ENZYME REGULATION.
RX   PubMed=11872754; DOI=10.1074/jbc.M201112200;
RA   Sigoillot F.D., Evans D.R., Guy H.I.;
RT   "Growth-dependent regulation of mammalian pyrimidine biosynthesis by
RT   the protein kinase A and MAPK signaling cascades.";
RL   J. Biol. Chem. 277:15745-15751(2002).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15890648; DOI=10.1074/jbc.M504581200;
RA   Sigoillot F.D., Kotsis D.H., Serre V., Sigoillot S.M., Evans D.R.,
RA   Guy H.I.;
RT   "Nuclear localization and mitogen-activated protein kinase
RT   phosphorylation of the multifunctional protein CAD.";
RL   J. Biol. Chem. 280:25611-25620(2005).
RN   [9]
RP   INDUCTION.
RX   PubMed=16155188; DOI=10.1093/nar/gki839;
RA   Chen K.F., Lai Y.Y., Sun H.S., Tsai S.J.;
RT   "Transcriptional repression of human cad gene by hypoxia inducible
RT   factor-1alpha.";
RL   Nucleic Acids Res. 33:5190-5198(2005).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1859, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1859, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [12]
RP   PHOSPHORYLATION AT THR-456; SER-1406; SER-1859 AND SER-1873, AND
RP   MUTAGENESIS OF SER-1873.
RX   PubMed=17485345; DOI=10.2741/2358;
RA   Sigoillot F.D., Kotsis D.H., Masko E.M., Bame M., Evans D.R.,
RA   Evans H.I.;
RT   "Protein kinase C modulates the up-regulation of the pyrimidine
RT   biosynthetic complex, CAD, by MAP kinase.";
RL   Front. Biosci. 12:3892-3898(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1859 AND THR-1884, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1884, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-747 AND LYS-1411, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1859 AND SER-1900, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1406 AND SER-1859, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1038; SER-1406;
RP   SER-1859; SER-1900 AND SER-1938, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   PHOSPHORYLATION AT SER-1859.
RX   PubMed=23429704; DOI=10.1126/science.1228771;
RA   Robitaille A.M., Christen S., Shimobayashi M., Cornu M., Fava L.L.,
RA   Moes S., Prescianotto-Baschong C., Sauer U., Jenoe P., Hall M.N.;
RT   "Quantitative phosphoproteomics reveal mTORC1 activates de novo
RT   pyrimidine synthesis.";
RL   Science 339:1320-1323(2013).
RN   [25]
RP   PHOSPHORYLATION AT SER-1859 AND SER-1900.
RX   PubMed=23429703; DOI=10.1126/science.1228792;
RA   Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D.;
RT   "Stimulation of de novo pyrimidine synthesis by growth signaling
RT   through mTOR and S6K1.";
RL   Science 339:1323-1328(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1859, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   INTERACTION WITH CIPC.
RX   PubMed=26657846; DOI=10.1016/j.bbrc.2015.11.117;
RA   Matsunaga R., Nishino T., Yokoyama A., Nakashima A., Kikkawa U.,
RA   Konishi H.;
RT   "Versatile function of the circadian protein CIPC as a regulator of
RT   Erk activation.";
RL   Biochem. Biophys. Res. Commun. 469:377-383(2016).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1456-1846 IN COMPLEX WITH
RP   DIHYDROOROTATE; N-CARBAMOYL-L-ASPARTIC ACID AND ZINC, COFACTOR,
RP   CATALYTIC ACTIVITY, FUNCTION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   MUTAGENESIS OF HIS-1471; THR-1562; PHE-1563; HIS-1590; CYS-1613;
RP   HIS-1614; GLU-1637 AND ASP-1686, AND CARBAMYLATION AT LYS-1556.
RX   PubMed=24332717; DOI=10.1016/j.str.2013.10.016;
RA   Grande-Garcia A., Lallous N., Diaz-Tejada C., Ramon-Maiques S.;
RT   "Structure, functional characterization, and evolution of the
RT   dihydroorotase domain of human CAD.";
RL   Structure 22:185-198(2014).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-177 AND CYS-735.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [30]
RP   INVOLVEMENT IN EIEE50, AND VARIANT EIEE50 GLN-2024.
RX   PubMed=25678555; DOI=10.1093/hmg/ddv057;
RA   Ng B.G., Wolfe L.A., Ichikawa M., Markello T., He M., Tifft C.J.,
RA   Gahl W.A., Freeze H.H.;
RT   "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis
RT   and decrease glycosylation precursors.";
RL   Hum. Mol. Genet. 24:3050-3057(2015).
RN   [31]
RP   VARIANTS EIEE50 ARG-33 AND 1789-ARG--PHE-2225 DEL.
RX   PubMed=28087732; DOI=10.1093/hmg/ddx018;
RA   Lohmann K., Masuho I., Patil D.N., Baumann H., Hebert E.,
RA   Steinruecke S., Trujillano D., Skamangas N.K., Dobricic V.,
RA   Huening I., Gillessen-Kaesbach G., Westenberger A.,
RA   Savic-Pavicevic D., Muenchau A., Oprea G., Klein C., Rolfs A.,
RA   Martemyanov K.A.;
RT   "Novel GNB1 mutations disrupt assembly and function of G protein
RT   heterotrimers and cause global developmental delay in humans.";
RL   Hum. Mol. Genet. 0:0-0(2017).
CC   -!- FUNCTION: This protein is a "fusion" protein encoding four
CC       enzymatic activities of the pyrimidine pathway (GATase, CPSase,
CC       ATCase and DHOase). {ECO:0000269|PubMed:24332717}.
CC   -!- CATALYTIC ACTIVITY: 2 ATP + L-glutamine + HCO(3)(-) + H(2)O = 2
CC       ADP + phosphate + L-glutamate + carbamoyl phosphate.
CC       {ECO:0000269|PubMed:24332717}.
CC   -!- CATALYTIC ACTIVITY: Carbamoyl phosphate + L-aspartate = phosphate
CC       + N-carbamoyl-L-aspartate. {ECO:0000269|PubMed:24332717}.
CC   -!- CATALYTIC ACTIVITY: (S)-dihydroorotate + H(2)O = N-carbamoyl-L-
CC       aspartate. {ECO:0000269|PubMed:24332717}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:24332717,
CC         ECO:0000269|PubMed:7766613};
CC       Note=Binds 3 Zn(2+) ions per subunit (for dihydroorotase
CC       activity). {ECO:0000269|PubMed:24332717,
CC       ECO:0000269|PubMed:7766613};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00409};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00409};
CC       Note=Binds 4 magnesium or manganese ions per subunit.
CC       {ECO:0000255|PROSITE-ProRule:PRU00409};
CC   -!- ENZYME REGULATION: Allosterically regulated and controlled by
CC       phosphorylation. 5-phosphoribose 1-diphosphate (PRPP) is an
CC       activator while UMP and UTP are inhibitors of the CPSase reaction.
CC       {ECO:0000269|PubMed:11872754}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=28 uM for dihydroorotate {ECO:0000269|PubMed:24332717};
CC         KM=241 uM for N-carbamoyl-L-aspartate
CC         {ECO:0000269|PubMed:24332717};
CC   -!- PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo
CC       pathway; (S)-dihydroorotate from bicarbonate: step 1/3.
CC       {ECO:0000269|PubMed:24332717}.
CC   -!- PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo
CC       pathway; (S)-dihydroorotate from bicarbonate: step 2/3.
CC       {ECO:0000269|PubMed:24332717}.
CC   -!- PATHWAY: Pyrimidine metabolism; UMP biosynthesis via de novo
CC       pathway; (S)-dihydroorotate from bicarbonate: step 3/3.
CC       {ECO:0000269|PubMed:24332717}.
CC   -!- SUBUNIT: Homohexamer (PubMed:24332717). Interacts with CIPC
CC       (PubMed:26657846). {ECO:0000269|PubMed:24332717,
CC       ECO:0000269|PubMed:26657846}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15890648}.
CC       Nucleus {ECO:0000269|PubMed:15890648}. Note=Cytosolic and
CC       unphosphorylated in resting cells, translocates to the nucleus in
CC       response to EGF stimulation, nuclear import promotes optimal cell
CC       growth.
CC   -!- INDUCTION: Transcriptionally repressed following hypoxia by HIF1A.
CC       {ECO:0000269|PubMed:16155188}.
CC   -!- PTM: Activated by MAP kinase (Erk1/2) phosphorylation just prior
CC       to the S phase of the cell cycle, when the demand for pyrimidine
CC       nucleotides is greatest, and down-regulated as the cells emerge
CC       from S phase by protein kinase A (PKA) phosphorylation.
CC       Phosphorylation at Ser-1859 by RPS6KB1 downstream of MTOR promotes
CC       oligomerization and stimulates dihydroorotase activity.
CC       Phosphorylation at Ser-1406 reduces sensitivy to feedback
CC       inhibition by UTP. {ECO:0000269|PubMed:17485345,
CC       ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704}.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 50 (EIEE50)
CC       [MIM:616457]: A form of epileptic encephalopathy, a heterogeneous
CC       group of severe childhood onset epilepsies characterized by
CC       refractory seizures, neurodevelopmental impairment, and poor
CC       prognosis. Development is normal prior to seizure onset, after
CC       which cognitive and motor delays become apparent. EIEE50 is an
CC       autosomal recessive, progressive disease with onset in infancy and
CC       favorable response to treatment with oral uridine.
CC       {ECO:0000269|PubMed:25678555, ECO:0000269|PubMed:28087732}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: GATase (glutamine amidotransferase) and CPSase
CC       (carbamoyl phosphate synthase) form together the glutamine-
CC       dependent CPSase (GD-CPSase) (EC 6.3.5.5). {ECO:0000305}.
CC   -!- SIMILARITY: In the central section; belongs to the DHOase family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Aspartate carbamoyltransferase
CC       entry;
CC       URL="https://en.wikipedia.org/wiki/Aspartate_carbamoyltransferase";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D78586; BAA11423.1; -; mRNA.
DR   EMBL; CH471053; EAX00612.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00613.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00614.1; -; Genomic_DNA.
DR   EMBL; BC014178; AAH14178.2; -; mRNA.
DR   EMBL; BC065510; AAH65510.1; -; mRNA.
DR   EMBL; M38561; AAA51907.1; -; Genomic_DNA.
DR   CCDS; CCDS1742.1; -.
DR   PIR; A36240; A36240.
DR   RefSeq; NP_001293008.1; NM_001306079.1.
DR   RefSeq; NP_004332.2; NM_004341.4.
DR   UniGene; Hs.377010; -.
DR   PDB; 4BY3; X-ray; 1.73 A; A=1456-1846.
DR   PDB; 4C6B; X-ray; 1.66 A; A=1456-1846.
DR   PDB; 4C6C; X-ray; 1.45 A; A=1456-1846.
DR   PDB; 4C6D; X-ray; 1.30 A; A=1456-1846.
DR   PDB; 4C6E; X-ray; 1.26 A; A=1456-1846.
DR   PDB; 4C6F; X-ray; 1.26 A; A=1456-1846.
DR   PDB; 4C6I; X-ray; 1.35 A; A=1456-1846.
DR   PDB; 4C6J; X-ray; 1.30 A; A=1456-1846.
DR   PDB; 4C6K; X-ray; 1.48 A; A=1456-1846.
DR   PDB; 4C6L; X-ray; 1.55 A; A=1456-1846.
DR   PDB; 4C6M; X-ray; 1.62 A; A=1456-1846.
DR   PDB; 4C6N; X-ray; 1.90 A; A=1456-1846.
DR   PDB; 4C6O; X-ray; 1.65 A; A=1456-1846.
DR   PDB; 4C6P; X-ray; 1.52 A; A=1456-1846.
DR   PDB; 4C6Q; X-ray; 1.66 A; A=1456-1846.
DR   PDB; 5G1N; X-ray; 2.10 A; A/B/C/D/E/F=1915-2225.
DR   PDB; 5G1O; X-ray; 2.10 A; A/B/C/D/E/F=1915-2225.
DR   PDB; 5G1P; X-ray; 3.19 A; A/B/C/D/E/F=1915-2225.
DR   PDBsum; 4BY3; -.
DR   PDBsum; 4C6B; -.
DR   PDBsum; 4C6C; -.
DR   PDBsum; 4C6D; -.
DR   PDBsum; 4C6E; -.
DR   PDBsum; 4C6F; -.
DR   PDBsum; 4C6I; -.
DR   PDBsum; 4C6J; -.
DR   PDBsum; 4C6K; -.
DR   PDBsum; 4C6L; -.
DR   PDBsum; 4C6M; -.
DR   PDBsum; 4C6N; -.
DR   PDBsum; 4C6O; -.
DR   PDBsum; 4C6P; -.
DR   PDBsum; 4C6Q; -.
DR   PDBsum; 5G1N; -.
DR   PDBsum; 5G1O; -.
DR   PDBsum; 5G1P; -.
DR   DisProt; DP01024; -.
DR   ProteinModelPortal; P27708; -.
DR   SMR; P27708; -.
DR   BioGrid; 107243; 108.
DR   DIP; DIP-39484N; -.
DR   IntAct; P27708; 44.
DR   MINT; MINT-5000537; -.
DR   STRING; 9606.ENSP00000264705; -.
DR   BindingDB; P27708; -.
DR   ChEMBL; CHEMBL3093; -.
DR   DrugBank; DB00128; L-Aspartic Acid.
DR   DrugBank; DB00130; L-Glutamine.
DR   DrugBank; DB03459; Sparfosic acid.
DR   MEROPS; M38.972; -.
DR   iPTMnet; P27708; -.
DR   PhosphoSitePlus; P27708; -.
DR   SwissPalm; P27708; -.
DR   BioMuta; CAD; -.
DR   DMDM; 50403731; -.
DR   EPD; P27708; -.
DR   MaxQB; P27708; -.
DR   PaxDb; P27708; -.
DR   PeptideAtlas; P27708; -.
DR   PRIDE; P27708; -.
DR   Ensembl; ENST00000264705; ENSP00000264705; ENSG00000084774.
DR   GeneID; 790; -.
DR   KEGG; hsa:790; -.
DR   UCSC; uc002rji.4; human.
DR   CTD; 790; -.
DR   DisGeNET; 790; -.
DR   GeneCards; CAD; -.
DR   HGNC; HGNC:1424; CAD.
DR   HPA; CAB007781; -.
DR   HPA; HPA057266; -.
DR   HPA; HPA069341; -.
DR   MalaCards; CAD; -.
DR   MIM; 114010; gene.
DR   MIM; 616457; phenotype.
DR   neXtProt; NX_P27708; -.
DR   OpenTargets; ENSG00000084774; -.
DR   PharmGKB; PA26023; -.
DR   eggNOG; KOG0370; Eukaryota.
DR   eggNOG; COG0458; LUCA.
DR   eggNOG; COG0505; LUCA.
DR   eggNOG; COG0540; LUCA.
DR   GeneTree; ENSGT00390000015604; -.
DR   HOGENOM; HOG000234584; -.
DR   HOVERGEN; HBG000279; -.
DR   InParanoid; P27708; -.
DR   KO; K11540; -.
DR   OrthoDB; EOG091G00DC; -.
DR   PhylomeDB; P27708; -.
DR   TreeFam; TF105604; -.
DR   BioCyc; MetaCyc:ENSG00000084774-MONOMER; -.
DR   BRENDA; 3.5.2.3; 2681.
DR   Reactome; R-HSA-500753; Pyrimidine biosynthesis.
DR   SIGNOR; P27708; -.
DR   UniPathway; UPA00070; UER00115.
DR   UniPathway; UPA00070; UER00116.
DR   UniPathway; UPA00070; UER00117.
DR   ChiTaRS; CAD; human.
DR   GenomeRNAi; 790; -.
DR   PMAP-CutDB; P27708; -.
DR   PRO; PR:P27708; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000084774; -.
DR   CleanEx; HS_CAD; -.
DR   ExpressionAtlas; P27708; baseline and differential.
DR   Genevisible; P27708; HS.
DR   GO; GO:0042995; C:cell projection; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; ISS:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:BHF-UCL.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0043234; C:protein complex; IEA:Ensembl.
DR   GO; GO:0043195; C:terminal bouton; ISS:BHF-UCL.
DR   GO; GO:0070335; F:aspartate binding; ISS:BHF-UCL.
DR   GO; GO:0004070; F:aspartate carbamoyltransferase activity; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; ISS:BHF-UCL.
DR   GO; GO:0004088; F:carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity; ISS:BHF-UCL.
DR   GO; GO:0004151; F:dihydroorotase activity; IDA:UniProtKB.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; ISS:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0006207; P:'de novo' pyrimidine nucleobase biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0044205; P:'de novo' UMP biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0019240; P:citrulline biosynthetic process; IEA:Ensembl.
DR   GO; GO:0017144; P:drug metabolic process; ISS:BHF-UCL.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0006541; P:glutamine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; ISS:BHF-UCL.
DR   GO; GO:0046134; P:pyrimidine nucleoside biosynthetic process; TAS:Reactome.
DR   GO; GO:0014075; P:response to amine; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0051414; P:response to cortisol; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0042594; P:response to starvation; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   GO; GO:0006228; P:UTP biosynthetic process; IEA:Ensembl.
DR   Gene3D; 1.10.1030.10; -; 1.
DR   Gene3D; 2.30.40.10; -; 2.
DR   Gene3D; 3.40.50.1370; -; 2.
DR   Gene3D; 3.40.50.1380; -; 1.
DR   Gene3D; 3.40.50.880; -; 1.
DR   Gene3D; 3.50.30.20; -; 1.
DR   HAMAP; MF_00001; Asp_carb_tr; 1.
DR   HAMAP; MF_01209; CPSase_S_chain; 1.
DR   InterPro; IPR006680; Amidohydro-rel.
DR   InterPro; IPR006132; Asp/Orn_carbamoyltranf_P-bd.
DR   InterPro; IPR006130; Asp/Orn_carbamoylTrfase.
DR   InterPro; IPR002082; Asp_carbamoyltransf.
DR   InterPro; IPR006131; Asp_carbamoyltransf_Asp/Orn-bd.
DR   InterPro; IPR011761; ATP-grasp.
DR   InterPro; IPR006275; CarbamoylP_synth_lsu.
DR   InterPro; IPR005480; CarbamoylP_synth_lsu_oligo.
DR   InterPro; IPR006274; CarbamoylP_synth_ssu.
DR   InterPro; IPR002474; CarbamoylP_synth_ssu_N.
DR   InterPro; IPR005479; CbamoylP_synth_lsu-like_ATP-bd.
DR   InterPro; IPR005483; CbamoylP_synth_lsu_CPSase_dom.
DR   InterPro; IPR029062; Class_I_gatase-like.
DR   InterPro; IPR002195; Dihydroorotase_CS.
DR   InterPro; IPR017926; GATASE.
DR   InterPro; IPR011059; Metal-dep_hydrolase_composite.
DR   InterPro; IPR032466; Metal_Hydrolase.
DR   InterPro; IPR011607; MGS-like_dom.
DR   InterPro; IPR016185; PreATP-grasp_dom.
DR   Pfam; PF01979; Amidohydro_1; 1.
DR   Pfam; PF02786; CPSase_L_D2; 2.
DR   Pfam; PF02787; CPSase_L_D3; 1.
DR   Pfam; PF00988; CPSase_sm_chain; 1.
DR   Pfam; PF00117; GATase; 1.
DR   Pfam; PF02142; MGS; 1.
DR   Pfam; PF00185; OTCace; 1.
DR   Pfam; PF02729; OTCace_N; 1.
DR   PRINTS; PR00100; AOTCASE.
DR   PRINTS; PR00101; ATCASE.
DR   PRINTS; PR00098; CPSASE.
DR   SMART; SM01096; CPSase_L_D3; 1.
DR   SMART; SM01097; CPSase_sm_chain; 1.
DR   SMART; SM00851; MGS; 1.
DR   SUPFAM; SSF48108; SSF48108; 1.
DR   SUPFAM; SSF51338; SSF51338; 1.
DR   SUPFAM; SSF51556; SSF51556; 1.
DR   SUPFAM; SSF52021; SSF52021; 1.
DR   SUPFAM; SSF52317; SSF52317; 1.
DR   SUPFAM; SSF52335; SSF52335; 1.
DR   SUPFAM; SSF52440; SSF52440; 2.
DR   SUPFAM; SSF53671; SSF53671; 1.
DR   TIGRFAMs; TIGR00670; asp_carb_tr; 1.
DR   TIGRFAMs; TIGR01369; CPSaseII_lrg; 1.
DR   TIGRFAMs; TIGR01368; CPSaseIIsmall; 1.
DR   PROSITE; PS50975; ATP_GRASP; 2.
DR   PROSITE; PS00097; CARBAMOYLTRANSFERASE; 1.
DR   PROSITE; PS00866; CPSASE_1; 2.
DR   PROSITE; PS00867; CPSASE_2; 2.
DR   PROSITE; PS00482; DIHYDROOROTASE_1; 1.
DR   PROSITE; PS00483; DIHYDROOROTASE_2; 1.
DR   PROSITE; PS51273; GATASE_TYPE_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; ATP-binding;
KW   Complete proteome; Congenital disorder of glycosylation; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Epilepsy; Hydrolase;
KW   Ligase; Magnesium; Manganese; Metal-binding; Multifunctional enzyme;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Pyrimidine biosynthesis; Reference proteome; Repeat; Transferase;
KW   Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.4}.
FT   CHAIN         2   2225       CAD protein.
FT                                /FTId=PRO_0000199506.
FT   DOMAIN      177    363       Glutamine amidotransferase type-1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00605}.
FT   DOMAIN      519    711       ATP-grasp 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00409}.
FT   DOMAIN     1052   1243       ATP-grasp 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00409}.
FT   NP_BIND     545    600       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00409}.
FT   NP_BIND    1078   1135       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00409}.
FT   REGION        2    365       GATase (Glutamine amidotransferase).
FT                                {ECO:0000250|UniProtKB:P08955}.
FT   REGION      366    394       Linker. {ECO:0000250|UniProtKB:P08955}.
FT   REGION      395   1455       CPSase (Carbamoyl-phosphate synthase).
FT                                {ECO:0000250|UniProtKB:P08955}.
FT   REGION      395    933       CPSase A. {ECO:0000250|UniProtKB:P08955}.
FT   REGION      934   1455       CPSase B. {ECO:0000250|UniProtKB:P08955}.
FT   REGION     1456   1788       DHOase (dihydroorotase).
FT                                {ECO:0000250|UniProtKB:P08955}.
FT   REGION     1789   1917       Linker. {ECO:0000250|UniProtKB:P08955}.
FT   REGION     1918   2225       ATCase (Aspartate transcarbamylase).
FT                                {ECO:0000250|UniProtKB:P08955}.
FT   ACT_SITE    252    252       Nucleophile; for GATase activity.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00605}.
FT   ACT_SITE    336    336       For GATase activity.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00605}.
FT   ACT_SITE    338    338       For GATase activity.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00605}.
FT   METAL       668    668       Magnesium or manganese 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL       682    682       Magnesium or manganese 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL       682    682       Magnesium or manganese 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL       684    684       Magnesium or manganese 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL      1202   1202       Magnesium or manganese 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL      1214   1214       Magnesium or manganese 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL      1214   1214       Magnesium or manganese 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL      1216   1216       Magnesium or manganese 4.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00409}.
FT   METAL      1471   1471       Zinc 1; via tele nitrogen.
FT                                {ECO:0000269|PubMed:24332717}.
FT   METAL      1471   1471       Zinc 2; via pros nitrogen.
FT                                {ECO:0000269|PubMed:24332717}.
FT   METAL      1473   1473       Zinc 1; via tele nitrogen.
FT                                {ECO:0000269|PubMed:24332717}.
FT   METAL      1556   1556       Zinc 1; via carbamate group.
FT                                {ECO:0000269|PubMed:24332717}.
FT   METAL      1556   1556       Zinc 3; via carbamate group.
FT                                {ECO:0000269|PubMed:24332717}.
FT   METAL      1590   1590       Zinc 3; via pros nitrogen.
FT                                {ECO:0000269|PubMed:24332717}.
FT   METAL      1613   1613       Zinc 2. {ECO:0000269|PubMed:24332717}.
FT   METAL      1614   1614       Zinc 3; via tele nitrogen.
FT                                {ECO:0000269|PubMed:24332717}.
FT   METAL      1637   1637       Zinc 2. {ECO:0000269|PubMed:24332717}.
FT   METAL      1686   1686       Zinc 1. {ECO:0000269|PubMed:24332717}.
FT   BINDING    1475   1475       N-carbamoyl-L-aspartate.
FT                                {ECO:0000269|PubMed:24332717}.
FT   BINDING    1505   1505       N-carbamoyl-L-aspartate.
FT                                {ECO:0000269|PubMed:24332717}.
FT   BINDING    1661   1661       N-carbamoyl-L-aspartate; via amide
FT                                nitrogen and carbonyl oxygen.
FT                                {ECO:0000269|PubMed:24332717}.
FT   BINDING    1686   1686       N-carbamoyl-L-aspartate.
FT                                {ECO:0000269|PubMed:24332717}.
FT   BINDING    1690   1690       N-carbamoyl-L-aspartate.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.4}.
FT   MOD_RES     456    456       Phosphothreonine; by MAPK1.
FT                                {ECO:0000269|PubMed:17485345}.
FT   MOD_RES     747    747       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1038   1038       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1406   1406       Phosphoserine; by PKA.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17485345}.
FT   MOD_RES    1411   1411       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1556   1556       N6-carboxylysine.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MOD_RES    1859   1859       Phosphoserine; by RPS6KB1 and PKA.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:17485345,
FT                                ECO:0000269|PubMed:23429703,
FT                                ECO:0000269|PubMed:23429704}.
FT   MOD_RES    1873   1873       Phosphoserine; by PKC; in vitro.
FT                                {ECO:0000269|PubMed:17485345}.
FT   MOD_RES    1884   1884       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976}.
FT   MOD_RES    1900   1900       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:23429703}.
FT   MOD_RES    1938   1938       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT      33     33       M -> R (in EIEE50; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078289.
FT   VARIANT     177    177       R -> Q (in a colorectal cancer sample;
FT                                somatic mutation; dbSNP:rs374122292).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035897.
FT   VARIANT     735    735       Y -> C (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035898.
FT   VARIANT    1789   2225       Missing (in EIEE50; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:28087732}.
FT                                /FTId=VAR_078290.
FT   VARIANT    2024   2024       R -> Q (in EIEE50; dbSNP:rs763410987).
FT                                {ECO:0000269|PubMed:25678555}.
FT                                /FTId=VAR_073955.
FT   MUTAGEN    1471   1471       H->A: No zinc-binding and no catalytic
FT                                activity. {ECO:0000269|PubMed:24332717,
FT                                ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1471   1471       H->N: Abolishes dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717,
FT                                ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1473   1473       H->A: No zinc-binding and no catalytic
FT                                activity. {ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1512   1512       D->N: No change in catalytic activity.
FT                                {ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1562   1562       T->A: Abolishes dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MUTAGEN    1563   1563       F->A: Abolishes dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MUTAGEN    1590   1590       H->A: Abolishes dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717,
FT                                ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1590   1590       H->N: No catalytic activity.
FT                                {ECO:0000269|PubMed:24332717,
FT                                ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1613   1613       C->S: Reduces dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MUTAGEN    1614   1614       H->A: Abolishes dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MUTAGEN    1637   1637       E->T: Abolishes dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MUTAGEN    1642   1642       H->N: 11.5% of wild-type catalytic
FT                                activity. {ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1686   1686       D->N: Abolishes dihydroorotase activity.
FT                                {ECO:0000269|PubMed:24332717}.
FT   MUTAGEN    1690   1690       H->N: 3% of wild-type catalytic activity.
FT                                {ECO:0000269|PubMed:7766613}.
FT   MUTAGEN    1873   1873       S->A: Abolishes PMA-induced Thr-456
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:17485345}.
FT   CONFLICT    505    505       P -> T (in Ref. 1; BAA11423).
FT                                {ECO:0000305}.
FT   CONFLICT    535    535       A -> G (in Ref. 1; BAA11423).
FT                                {ECO:0000305}.
FT   CONFLICT    560    560       L -> V (in Ref. 1; BAA11423).
FT                                {ECO:0000305}.
FT   CONFLICT   1103   1103       T -> A (in Ref. 1; BAA11423).
FT                                {ECO:0000305}.
FT   CONFLICT   1513   1513       A -> G (in Ref. 1; BAA11423).
FT                                {ECO:0000305}.
FT   CONFLICT   1676   1676       N -> D (in Ref. 1; BAA11423).
FT                                {ECO:0000305}.
FT   STRAND     1462   1465       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1467   1472       {ECO:0000244|PDB:4C6F}.
FT   TURN       1476   1478       {ECO:0000244|PDB:4C6F}.
FT   TURN       1480   1482       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1485   1494       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1497   1502       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1506   1508       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1513   1526       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1528   1533       {ECO:0000244|PDB:4C6F}.
FT   TURN       1546   1548       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1549   1551       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1555   1558       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1560   1563       {ECO:0000244|PDB:4C6F}.
FT   TURN       1564   1566       {ECO:0000244|PDB:4C6C}.
FT   HELIX      1571   1580       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1587   1590       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1594   1605       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1610   1612       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1618   1629       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1634   1638       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1640   1644       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1647   1649       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1650   1657       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1667   1675       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1677   1679       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1692   1695       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1697   1699       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1707   1719       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1725   1732       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1734   1740       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1749   1759       {ECO:0000244|PDB:4C6F}.
FT   TURN       1773   1776       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1778   1788       {ECO:0000244|PDB:4C6F}.
FT   STRAND     1791   1795       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1809   1811       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1813   1815       {ECO:0000244|PDB:4C6F}.
FT   HELIX      1929   1931       {ECO:0000244|PDB:5G1N}.
FT   HELIX      1934   1952       {ECO:0000244|PDB:5G1N}.
FT   TURN       1959   1962       {ECO:0000244|PDB:5G1N}.
FT   STRAND     1964   1971       {ECO:0000244|PDB:5G1N}.
FT   HELIX      1975   1986       {ECO:0000244|PDB:5G1N}.
FT   STRAND     1990   1995       {ECO:0000244|PDB:5G1N}.
FT   HELIX      1996   1998       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2000   2003       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2007   2014       {ECO:0000244|PDB:5G1N}.
FT   TURN       2015   2017       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2019   2027       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2030   2035       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2042   2047       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2053   2067       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2074   2079       {ECO:0000244|PDB:5G1N}.
FT   TURN       2081   2083       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2085   2094       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2100   2104       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2107   2109       {ECO:0000244|PDB:5G1P}.
FT   HELIX      2113   2121       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2126   2131       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2132   2135       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2136   2138       {ECO:0000244|PDB:5G1O}.
FT   STRAND     2140   2144       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2149   2151       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2155   2160       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2169   2172       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2180   2182       {ECO:0000244|PDB:5G1N}.
FT   STRAND     2188   2191       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2193   2195       {ECO:0000244|PDB:5G1N}.
FT   HELIX      2203   2221       {ECO:0000244|PDB:5G1N}.
SQ   SEQUENCE   2225 AA;  242984 MW;  2AB8E8413E825A8F CRC64;
     MAALVLEDGS VLRGQPFGAA VSTAGEVVFQ TGMVGYPEAL TDPSYKAQIL VLTYPLIGNY
     GIPPDEMDEF GLCKWFESSG IHVAALVVGE CCPTPSHWSA TRTLHEWLQQ HGIPGLQGVD
     TRELTKKLRE QGSLLGKLVQ NGTEPSSLPF LDPNARPLVP EVSIKTPRVF NTGGAPRILA
     LDCGLKYNQI RCLCQRGAEV TVVPWDHALD SQEYEGLFLS NGPGDPASYP SVVSTLSRVL
     SEPNPRPVFG ICLGHQLLAL AIGAKTYKMR YGNRGHNQPC LLVGSGRCFL TSQNHGFAVE
     TDSLPADWAP LFTNANDGSN EGIVHNSLPF FSVQFHPEHQ AGPSDMELLF DIFLETVKEA
     TAGNPGGQTV RERLTERLCP PGIPTPGSGL PPPRKVLILG SGGLSIGQAG EFDYSGSQAI
     KALKEENIQT LLINPNIATV QTSQGLADKV YFLPITPHYV TQVIRNERPD GVLLTFGGQT
     ALNCGVELTK AGVLARYGVR VLGTPVETIE LTEDRRAFAA RMAEIGEHVA PSEAANSLEQ
     AQAAAERLGY PVLVRAAFAL GGLGSGFASN REELSALVAP AFAHTSQVLV DKSLKGWKEI
     EYEVVRDAYG NCVTVCNMEN LDPLGIHTGE SIVVAPSQTL NDREYQLLRQ TAIKVTQHLG
     IVGECNVQYA LNPESEQYYI IEVNARLSRS SALASKATGY PLAYVAAKLA LGIPLPELRN
     SVTGGTAAFE PSVDYCVVKI PRWDLSKFLR VSTKIGSCMK SVGEVMGIGR SFEEAFQKAL
     RMVDENCVGF DHTVKPVSDM ELETPTDKRI FVVAAALWAG YSVDRLYELT RIDRWFLHRM
     KRIIAHAQLL EQHRGQPLPP DLLQQAKCLG FSDKQIALAV LSTELAVRKL RQELGICPAV
     KQIDTVAAEW PAQTNYLYLT YWGTTHDLTF RTPHVLVLGS GVYRIGSSVE FDWCAVGCIQ
     QLRKMGYKTI MVNYNPETVS TDYDMCDRLY FDEISFEVVM DIYELENPEG VILSMGGQLP
     NNMAMALHRQ QCRVLGTSPE AIDSAENRFK FSRLLDTIGI SQPQWRELSD LESARQFCQT
     VGYPCVVRPS YVLSGAAMNV AYTDGDLERF LSSAAAVSKE HPVVISKFIQ EAKEIDVDAV
     ASDGVVAAIA ISEHVENAGV HSGDATLVTP PQDITAKTLE RIKAIVHAVG QELQVTGPFN
     LQLIAKDDQL KVIECNVRVS RSFPFVSKTL GVDLVALATR VIMGEEVEPV GLMTGSGVVG
     VKVPQFSFSR LAGADVVLGV EMTSTGEVAG FGESRCEAYL KAMLSTGFKI PKKNILLTIG
     SYKNKSELLP TVRLLESLGY SLYASLGTAD FYTEHGVKVT AVDWHFEEAV DGECPPQRSI
     LEQLAEKNFE LVINLSMRGA GGRRLSSFVT KGYRTRRLAA DFSVPLIIDI KCTKLFVEAL
     GQIGPAPPLK VHVDCMTSQK LVRLPGLIDV HVHLREPGGT HKEDFASGTA AALAGGITMV
     CAMPNTRPPI IDAPALALAQ KLAEAGARCD FALFLGASSE NAGTLGTVAG SAAGLKLYLN
     ETFSELRLDS VVQWMEHFET WPSHLPIVAH AEQQTVAAVL MVAQLTQRSV HICHVARKEE
     ILLIKAAKAR GLPVTCEVAP HHLFLSHDDL ERLGPGKGEV RPELGSRQDV EALWENMAVI
     DCFASDHAPH TLEEKCGSRP PPGFPGLETM LPLLLTAVSE GRLSLDDLLQ RLHHNPRRIF
     HLPPQEDTYV EVDLEHEWTI PSHMPFSKAH WTPFEGQKVK GTVRRVVLRG EVAYIDGQVL
     VPPGYGQDVR KWPQGAVPQL PPSAPATSEM TTTPERPRRG IPGLPDGRFH LPPRIHRASD
     PGLPAEEPKE KSSRKVAEPE LMGTPDGTCY PPPPVPRQAS PQNLGTPGLL HPQTSPLLHS
     LVGQHILSVQ QFTKDQMSHL FNVAHTLRMM VQKERSLDIL KGKVMASMFY EVSTRTSSSF
     AAAMARLGGA VLSFSEATSS VQKGESLADS VQTMSCYADV VVLRHPQPGA VELAAKHCRR
     PVINAGDGVG EHPTQALLDI FTIREELGTV NGMTITMVGD LKHGRTVHSL ACLLTQYRVS
     LRYVAPPSLR MPPTVRAFVA SRGTKQEEFE SIEEALPDTD VLYMTRIQKE RFGSTQEYEA
     CFGQFILTPH IMTRAKKKMV VMHPMPRVNE ISVEVDSDPR AAYFRQAENG MYIRMALLAT
     VLGRF
//
